Luteinizing hormone upregulates survivin and inhibits apoptosis in ovarian epithelial tumors

详细信息    查看全文

• 作者：Zhenbo Zhang^a ; ¹ ; Hong Liao^b ; ¹ ; Xiaojun Chen^c ; Yu Zheng^c ; Yingtao Liu^c ; Xiang Tao^c ; Chao Gu^c ; Lingling Dong^b ; Tao Duan^b ; Yixia Yang^a ; Xuelian Liu^a ; Yinhua Yu^c ; Youji Feng^a ; ^{fengyj4806@sohu.com}
• 关键词：Survivin ; Ovarian cancer ; Luteinizing hormone ; Apoptosis
• 刊名：European Journal of Obstetrics and Gynecology and Reproductive Biology
• 出版年：2011
• 出版时间：March 2011
• 年：2011
• 卷：155
• 期：1
• 页码：69-74
• 全文大小：299 K

文摘

Objective

Luteinizing hormone (LH) plays an important role in the development of ovarian cancer, and has been shown to inhibit apoptosis in ovarian cancer cells. Similarly, survivin is a molecule that has been shown to inhibit apoptosis in other types of cancer. Therefore, the aim of this study was to determine whether survivin can be induced by LH in ovarian cancer, and whether this induction influences the sensitivity of ovarian cancers to chemotherapy.

Study design

Survivin expression was monitored using western blot assays, and flow cytometry was used to detect the effects of cisplatin on the induction of apoptosis by LH. MTT assays were also used to analyze rates of cell proliferation.

Results

Administration of LH in vitro induced survivin expression in a dose-dependent manner. Moreover, this signaling was dependent on the ERK1/2 signaling pathway. LH also blocked apoptosis induced by cisplatin.

Conclusion

These results suggest that LH influences the sensitivity of ovarian cancer cells to chemotherapy via signaling to inhibit apoptosis that also upregulates survivin.